PrimeRFP SCOUT · Federal Contract Recompete Brief

W81XWH20C0030PHASE II clinical TRIAL — Cellphire, Inc

Cellphire, Inc holds $49.4M across 1 federal awards, concentrated at Department of Defense (DOD). Competition previously drew 3 offers. Set-aside status: SBA. Recompete timing centers on the Oct 31, 2028 PoP end — agencies typically plan 12–18 months ahead.

W4pz Usa Med Rsch Acquis Act

Awarding office

Cellphire, Inc

Recipient

Oct 31, 2028

PoP end

$57.9M

Obligated

541715

NAICS

AN94

PSC

SBA

Set-aside

3 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Cellphire, Inc — $90

Contract facts

SBA

Contract numberW81XWH20C0030

Also listed asW81XWH-20-C-0030

AgencyW4pz Usa Med Rsch Acquis Act

Awarding officeW4pz Usa Med Rsch Acquis Act

IncumbentCellphire, Inc

UEIF42VPQJ8LJL4

NAICS541715

PSCAN94

Place of performanceROCKVILLE, MD

Related solicitationW81XWH19R0033

PoP end (current)Oct 31, 2028

Obligated$57.9M

PHASE II CLINICAL TRIAL is a federal SBA award for W4pz Usa Med Rsch Acquis Act held by Cellphire, Inc. Estimated value $70.3M ($57.9M obligated). Current period of performance ends Oct 31, 2028. Last award drew 3 bidders. Place of performance: ROCKVILLE, MD. Related solicitation W81XWH19R0033.

Recompete timing

Public

● Expiring in 786 days

Current PoP ends Oct 31, 2028 (786 days remaining). Agencies typically plan 12–18 months ahead — capture window opens around May 1, 2027.

Incumbent footprint

Public record

Cellphire, Inc — $49.4M obligated across 1 awards (firm-wide, all agencies).

Sole agency: Department of Defense (DOD)

Department of Defense (DOD)$49.4M · 100% of firm total

Open full company profile →

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract W81XWH20C0030?

W81XWH20C0030 (PHASE II clinical TRIAL) is a W4pz Usa Med Rsch Acquis Act award with an estimated value of $70.3M, currently held by Cellphire, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is W81XWH-20-C-0030?

W81XWH-20-C-0030 is the dashed form of PIID W81XWH20C0030 (PHASE II clinical TRIAL), held by Cellphire, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded W81XWH20C0030?

W4pz Usa Med Rsch Acquis Act awarded W81XWH20C0030 to Cellphire, Inc.

Who is the incumbent on W81XWH20C0030?

Cellphire, Inc is the incumbent with $49.4M across 1 related awards in SCOUT’s public footprint. The current period of performance ends Oct 31, 2028.

When does Cellphire, Inc’s W81XWH20C0030 come up for recompete?

SCOUT tracks a period-of-performance end of Oct 31, 2028. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Seen enough? Run one full capture cycle on W81XWH20C0030 — $90 for 90 days.

This page stays free. Pilot is the live layer: displacement scoring, recompete pipeline, Daily Brief, and SCOUT MCP for 90 days. If you already live in Claude or ChatGPT and only need live search, start MCP Explorer at $29/mo.

Start Pilot — $90

$1/day · one payment · no subscription

Use SCOUT in your AI client — $29/mo

Classify + search inside Claude, ChatGPT, Cursor

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 20, 2026 · refreshed monthlyLatest procurement action Apr 14, 2026